Skip to main content
. 2016 Dec 16;95(50):e5599. doi: 10.1097/MD.0000000000005599

Figure 2.

Figure 2

The forest plot of the meta-analysis based on the type of molecular targeted agent (MTA) and race for the overall survival (A and B), progression-free survival (C and D), and overall response rate (E and F) of platinum–gemcitabine (PG) plus MTA and PG for non-small cell lung cancer.